Great Lakes Advisors LLC Invests $1.25 Million in Edwards Lifesciences Corporation $EW

Key Points

• Great Lakes Advisors initiated a $1.25 million position in Edwards Lifesciences during the second quarter, while institutional investors collectively own 79.46% of the company.
• Analyst sentiment is generally positive: 17 analysts rate the stock a Buy and six rate it a Hold, producing a “Moderate Buy” consensus and an average price target of $100.27.
• Edwards exceeded quarterly expectations with adjusted earnings of $0.78 per share and revenue of $1.74 billion, up 13.6% year over year; however, company insiders sold 25,570 shares worth about $2.22 million over the past 90 days.

Great Lakes Advisors LLC bought a new stake in Edwards Lifesciences Corporation (NYSE:EW - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 13,877 shares of the medical research company's stock, valued at approximately $1,255,000.

Other hedge funds also recently modified their holdings of the company. BlackRock Inc. bought a new position in Edwards Lifesciences during the 2nd quarter valued at $5,318,092,000. Bank of New York Mellon Corp bought a new stake in shares of Edwards Lifesciences in the 2nd quarter worth $1,274,082,000. Norges Bank purchased a new stake in shares of Edwards Lifesciences in the fourth quarter valued at about $803,686,000. Deutsche Bank AG bought a new position in shares of Edwards Lifesciences during the second quarter valued at about $516,552,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Edwards Lifesciences by 278.3% during the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company's stock valued at $434,318,000 after purchasing an additional 4,108,270 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company's stock.

Analyst Upgrades and Downgrades

EW has been the subject of a number of recent analyst reports. Barclays reaffirmed an "overweight" rating and issued a $110.00 price objective (up from $104.00) on shares of Edwards Lifesciences in a research report on Monday, April 27th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Edwards Lifesciences in a report on Friday, July 17th. Mizuho increased their price target on Edwards Lifesciences from $100.00 to $105.00 and gave the company an "outperform" rating in a research report on Wednesday, July 15th. Leerink Partners upgraded Edwards Lifesciences from a "market perform" rating to an "outperform" rating and lifted their price target for the stock from $87.00 to $101.00 in a report on Friday, July 24th. Finally, Evercore reissued an "outperform" rating and issued a $100.00 price objective on shares of Edwards Lifesciences in a research report on Monday, July 6th. Seventeen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. According to data from MarketBeat, Edwards Lifesciences presently has a consensus rating of "Moderate Buy" and an average price target of $100.27.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, SVP Andrew M. Dahl sold 568 shares of the stock in a transaction on Friday, May 29th. The stock was sold at an average price of $86.08, for a total transaction of $48,893.44. Following the completion of the transaction, the senior vice president directly owned 15,334 shares of the company's stock, valued at approximately $1,319,950.72. This represents a 3.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the firm's stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total value of $2,000,190.90. Following the completion of the sale, the vice president directly owned 98,611 shares of the company's stock, valued at $8,521,962.62. This represents a 19.01% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 25,570 shares of company stock valued at $2,219,390. Company insiders own 0.31% of the company's stock.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $89.89 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52. The firm has a market cap of $51.76 billion, a price-to-earnings ratio of 51.66, a P/E/G ratio of 2.26 and a beta of 0.85. Edwards Lifesciences Corporation has a 52 week low of $72.30 and a 52 week high of $96.29. The firm's 50-day simple moving average is $89.21 and its two-hundred day simple moving average is $84.67.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating analysts' consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The firm had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.70 billion. During the same period in the prior year, the firm earned $0.67 EPS. The company's revenue was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, equities analysts forecast that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source